Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.

Cuncannon M, Wong M, Jayamanne D, Guo L, Cove N, Wheeler H, Back M.

BMC Cancer. 2019 May 14;19(1):445. doi: 10.1186/s12885-019-5678-1.

2.

Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Back M, Gzell CE, Kastelan M, Guo L, Wheeler HR.

Neurooncol Pract. 2015 Mar;2(1):48-53. Epub 2014 Dec 15.

3.

Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?

Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, Champ CE, Zhang I, Bar-Ad V, Kim L, Glass J, Evans JJ, Andrews DW, Werner-Wasik M, Shi W.

J Neurooncol. 2018 Dec;140(3):623-628. doi: 10.1007/s11060-018-2989-z. Epub 2018 Sep 4.

PMID:
30182159
4.

Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.

Anderson MD, Hamza MA, Hess KR, Puduvalli VK.

Neuro Oncol. 2014 Jun;16(6):823-8. doi: 10.1093/neuonc/nou021. Epub 2014 Mar 3.

5.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

6.

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J.

Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28.

PMID:
30266892
7.

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.

Shields LB, Kadner R, Vitaz TW, Spalding AC.

Radiat Oncol. 2013 Apr 25;8:101. doi: 10.1186/1748-717X-8-101.

8.

Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.

Fleischmann DF, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, Unterrainer M, Thon N, Kreth FW, Belka C, Niyazi M.

Radiother Oncol. 2019 Jun 25;138:99-105. doi: 10.1016/j.radonc.2019.06.009. [Epub ahead of print]

PMID:
31252301
9.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
10.

Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.

Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, Gilbert MR, Lassman AB.

J Neurooncol. 2012 Apr;107(2):407-11. doi: 10.1007/s11060-011-0768-1. Epub 2011 Dec 28.

PMID:
22203237
11.
12.

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, Ghiringhelli F, Guillamo JS, Durando X, Castera D, Frenay M, Campello C, Dalban C, Skrzypski J, Chinot O.

Ann Oncol. 2014 Jul;25(7):1442-7. doi: 10.1093/annonc/mdu148. Epub 2014 Apr 9.

PMID:
24723487
13.

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.

Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M.

J Neurooncol. 2016 Dec;130(3):591-599. Epub 2016 Sep 6.

PMID:
27599828
14.

Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.

Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A.

J Neurooncol. 2016 Feb;126(3):567-75. doi: 10.1007/s11060-015-2002-z. Epub 2015 Nov 27.

PMID:
26614518
15.

Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.

Jakobsen JN, Urup T, Grunnet K, Toft A, Johansen MD, Poulsen SH, Christensen IJ, Muhic A, Poulsen HS.

J Neurooncol. 2018 Apr;137(2):439-446. doi: 10.1007/s11060-017-2736-x. Epub 2018 Jan 12.

PMID:
29330749
16.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
17.

The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.

Kaloshi G, Diamandi P, Cakani B, Brace G, Rroji A, Petrela M.

Tumori. 2015 Jan-Feb;101(1):41-5. doi: 10.5301/tj.5000210. Epub 2015 Feb 11.

PMID:
25702676
18.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.

J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.

PMID:
27918718
19.

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U.

Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23.

PMID:
24456504
20.

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.

Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, Hui RL, Chen DM.

J Neurooncol. 2015 Mar;122(1):145-50. doi: 10.1007/s11060-014-1693-x. Epub 2015 Jan 11.

PMID:
25575937

Supplemental Content

Support Center